In vitro studies with sisomicin, gentamicin and tobramycin

Shadomy, Smith; Utz, C.; Shadomy, H. Jean

doi:10.1007/bf01646956

Infection

1976

DOI: 10.1007/bf01646956

|View full text |Cite

In vitro studies with sisomicin, gentamicin and tobramycin

Smith Shadomy

C. Utz

H. Jean Shadomy

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

1978

1986

Publication Types

Select...

Article6

Relationship

Self Cite0

Independent6

Authors

Journals

Cited by 6 publications

(1 citation statement)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Ticarcillin, a newer semi synthetic penicillin has been shown to be more active than carbenicillin against F. aeruginosa [11]. Sisomicin and netilmicin are two new semisynthetic aminoglycosides closely related to gentamicin Cla, a compo nent of the gentamicin complex [5,7,12]. Sisomicin is more active than gentamicin against F. aeruginosa [7], In animal studies, it has been shown that netilmicin is much less nephrotoxic than gentamicin [4].…”

mentioning

confidence: 99%

In vitro Activity of Carbenicillin, Ticarcillin, Sisomicin and Netilmicin Alone and in Combination Against Pseudomonas aeruginosa

Watanakunakorn

Glotzbecker

1978

Chemotherapy

View full text Add to dashboard Cite

The in vitro activity of carbenicillin, ticarcillin, sisomicin and netilmicin alone and in combination against 35 strains of Pseudomonas aeruginosa was investigated. Ticarcillin was more active than carbenicillin and sisomicin was more active than netilmicin. There was enhanced killing of many strains of P. aeruginosa by the combination of carbenicillin or ticarcillin with sisomicin or netilmicin.

show abstract

mentioning

confidence: 99%

In vitro Activity of Carbenicillin, Ticarcillin, Sisomicin and Netilmicin Alone and in Combination Against Pseudomonas aeruginosa

Watanakunakorn

Glotzbecker

1978

Chemotherapy

View full text Add to dashboard Cite

show abstract

Erfahrungen mit Sisomicin in der Pädiatrie

et al. 1979

View full text Add to dashboard Cite

Sisomicin, an aminoglycoside antibiotic, is especially effective against Escherichia coli, Klebsiella, Enterobacter, Citrobacter, Serratia, indole-positive and indole-negative Proteus species, Pseudomonas aeruginosa, Salmonella and Staphylococcus aureus. It has a bactericidal action. Although sisomicin is similar to the other aminoglycoside antibiotics, there is not complete cross-resistance to them. Our own pharmacokinetic investigations showed that a dose of 2--3 mg/kg body weight of sisomicin twice daily is necessary in the neonatal period. Infants should be given 2.5 mg/kg body weight three times daily, and school children 1.5--20 mg/kg body weight, likewise three times daily. Excretion of sisomicin in the urine is lower in children than in adults, amounting within 24 hours to only 10--20% in newborns, and 30--40% in school-children. Sisomicin induces excretion of some enzymes in higher quantities from the tubular part of the kidneys, especially alaninaminopeptidase. A report is given on 58 patients, especially newborns and prematures, who were treated for about seven days with sisomicin. The results obtained with a wide variety of infections (such as omphalitis, aspiration of amniotic fluid with broncho-pneumonia, phlegmons of the galea, and also pyelonephritis and mucoviscidosis with pulmonary complications) can be described as good, with a success rate of 85%. On only seven occasions were insignificant transitory side-effects, such as slight increase in transaminases, toxic-allergic exanthema and pain in the region in injection, observed.

show abstract

N-Formimidoyl-Thienamycin: In-vitro-Aktivität bei Bakterien mit Resistenz gegen Beta-Laktam-Antibiotika oder Gentamicin

Bartmann¹,

Tarbuc²

1982

Infection

View full text Add to dashboard Cite

The minimum inhibitory concentration (MIC) and the minimum bactericidal concentration (MBC) of N-formimidoyl-thienamycin were determined for 25 strains each of Escherichia coli, Klebsiella pneumoniae, Enterobacter cloacae, Serratia marcescens and Pseudomonas aeruginosa which were resistant to gentamicin and/or acylureido penicillins or cefotaxime, cefoperazone or moxalactam, and for 38 strains of the group D streptococci. The drug was very active against the most frequently encountered gram-negative resistant causative organisms of nosocomial infections. The MIC ranged from 0.25-1 mg/l for multiresistant Enterobacteriaceae, and from 0.5-4 mg/l for multiresistant P. aeruginosa. The group D streptococci (enterococci) showed a low MIC (median: 0.75 mg/l); the median of the MBC was greater than 64 mg/l, however.

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

In vitro studies with sisomicin, gentamicin and tobramycin

Cited by 6 publications

References 8 publications

<i>In vitro</i> Activity of Carbenicillin, Ticarcillin, Sisomicin and Netilmicin Alone and in Combination Against <i>Pseudomonas aeruginosa</i>

<i>In vitro</i> Activity of Carbenicillin, Ticarcillin, Sisomicin and Netilmicin Alone and in Combination Against <i>Pseudomonas aeruginosa</i>

Erfahrungen mit Sisomicin in der Pädiatrie

N-Formimidoyl-Thienamycin: In-vitro-Aktivität bei Bakterien mit Resistenz gegen Beta-Laktam-Antibiotika oder Gentamicin

Contact Info

Product

Resources

About